{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:54:50Z","timestamp":1793213690692,"version":"4.5.0"},"reference-count":122,"publisher":"American Society of Clinical Oncology (ASCO)","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"abstract":"<jats:p>Adoptive cellular immunotherapy (ACT) has revolutionized hematologic malignancies, yet translation to solid tumors has historically been limited. This landscape shifted significantly in 2024 with US Food and Drug Administration approvals of lifileucel, a tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma, and afamitresgene autoleucel, an engineered T-cell receptor (TCR) therapy for synovial sarcoma. These approvals mark the clinical arrival of ACT for solid tumors and highlight a rapidly expanding therapeutic landscape. Beyond these indications, multiple ACT platforms including TIL, TCR, chimeric antigen receptor (CAR) T-cell, CAR-natural killer, and CAR-macrophage therapies are under active clinical investigation across diverse solid tumor indications. Clinical experience to date has defined key barriers to efficacy, including impaired tumor trafficking, antigen heterogeneity, immunosuppressive tumor microenvironment, and limited cellular persistence. In parallel, rapid advances in cellular engineering are reshaping the field, with the development of armored constructs, logic-gated and multiantigen targeting strategies, innate immune\u2013based platforms, and novel manufacturing approaches including allogeneic and in vivo cell engineering. As ACT enters clinical practice for select solid tumors, distinct toxicity profiles and logistical requirements necessitate careful patient selection and multidisciplinary coordination. Early biomarker testing, timely referral to specialized centers, and familiarity with evolving toxicity management frameworks are increasingly critical. Here, we seek to provide a practice-oriented framework for understanding emerging ACT platforms, clinical data, toxicity considerations, and implementation strategies relevant to contemporary solid tumor oncology care.<\/jats:p>","DOI":"10.1200\/op-26-00119","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T19:59:23Z","timestamp":1779307163000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":2,"title":["Cellular Therapies in Solid Tumors: Are We Ready for Primetime?"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7815-3101","authenticated-orcid":true,"given":"Giuseppe","family":"Maiocco","sequence":"first","affiliation":[{"name":"Division of Internal Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1865-5801","authenticated-orcid":true,"given":"Vinicius","family":"Ernani","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5514-7072","authenticated-orcid":true,"given":"Michael P.","family":"Gustafson","sequence":"additional","affiliation":[{"name":"Human Cell Therapy Laboratory, Division of Transfusion Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7613-6305","authenticated-orcid":true,"given":"Salman R.","family":"Punekar","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Medicine, Laura and Isaac Perlmutter Cancer Center, New York University (NYU) Grossman School of Medicine, NYU Langone Health, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9784-8603","authenticated-orcid":true,"given":"Konstantinos","family":"Leventakos","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Molina","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9480-2626","authenticated-orcid":true,"given":"Yousef","family":"Zakharia","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2700-2658","authenticated-orcid":true,"given":"Mitesh","family":"Borad","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2938-3730","authenticated-orcid":true,"given":"Antonious Z.","family":"Hazim","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01222-8"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27892"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-024-00750-2"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-025-00695-8"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1638186"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02386-8"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02280-1"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02334-6"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00704-3"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03938-0"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-0880"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-0595"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.11.015"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1018962"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0116"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-169"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174160"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00765"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2024-000566"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.794183"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00291-0"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0812-8"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2016.12.006"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05703-9"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.835762"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1121030"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003487"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.162"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abe2606"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2018.12.009"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20230903"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1519671"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00373-7"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01207-0"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-025-00654-3"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2024.01.01"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2025.06.006"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0462-y"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.4133"},{"key":"e_1_3_6_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2332"},{"key":"e_1_3_6_46_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.783305"},{"key":"e_1_3_6_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.06.010"},{"key":"e_1_3_6_48_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005755"},{"key":"e_1_3_6_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00319-2"},{"key":"e_1_3_6_50_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210233"},{"key":"e_1_3_6_51_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-1334"},{"key":"e_1_3_6_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00860-8"},{"key":"e_1_3_6_53_2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.4_suppl.TPS788","article-title":"EVEREST-2: A seamless phase 1\/2 study of A2B694, a logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy, in patients with pancreatic cancer (PANC) or other mesothelin (MSLN)-expressing solid tumors and human leukocyte antigen (HLA)\u2013A*02 loss of heterozygosity (LOH)","volume":"43","author":"Spencer KR","year":"2025","unstructured":"Spencer KR, Punekar SR, Grierson P, et al: EVEREST-2: A seamless phase 1\/2 study of A2B694, a logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy, in patients with pancreatic cancer (PANC) or other mesothelin (MSLN)-expressing solid tumors and human leukocyte antigen (HLA)\u2013A*02 loss of heterozygosity (LOH). J Clin Oncol 43, 2025 (suppl 4; abstr TPS788)","journal-title":"J Clin Oncol"},{"key":"e_1_3_6_54_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2699"},{"key":"e_1_3_6_55_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-SITC2025.0535"},{"key":"e_1_3_6_56_2","article-title":"697 A phase 1 study of AMG 119, a DLL3-targeting, chimeric antigen receptor (CAR) T cell therapy, in relapsed\/refractory small cell lung cancer (SCLC)","author":"Byers L","year":"2022","unstructured":"Byers L, Heymach J, Gibbons D, et al: 697 A phase 1 study of AMG 119, a DLL3-targeting, chimeric antigen receptor (CAR) T cell therapy, in relapsed\/refractory small cell lung cancer (SCLC). J Immunother Cancer 10(Suppl 2): A728, 2022","journal-title":"J Immunother Cancer"},{"key":"e_1_3_6_57_2","volume-title":"Patients With Small Cell Lung Cancer. IASLC 2021 World Conference on Lung Cancer","author":"Owings A","year":"2021","unstructured":"Owings A, Byers LA, Heymach J, et al: A phase 1 study of AMG 119, a DLL3-targeting CAR T cell therapy, in Patients With Small Cell Lung Cancer. IASLC 2021 World Conference on Lung Cancer, 2021"},{"key":"e_1_3_6_58_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01466"},{"key":"e_1_3_6_59_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.2500"},{"key":"e_1_3_6_60_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03650-6"},{"key":"e_1_3_6_61_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS2673"},{"key":"e_1_3_6_62_2","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2021.986"},{"key":"e_1_3_6_63_2","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14523"},{"key":"e_1_3_6_64_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.726492"},{"key":"e_1_3_6_65_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605274"},{"key":"e_1_3_6_66_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.9548"},{"key":"e_1_3_6_67_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02875-1"},{"key":"e_1_3_6_68_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3833"},{"key":"e_1_3_6_69_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11869-4"},{"key":"e_1_3_6_70_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.628906"},{"key":"e_1_3_6_71_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02325-5"},{"key":"e_1_3_6_72_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-021-00303-x"},{"key":"e_1_3_6_73_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1286750"},{"key":"e_1_3_6_74_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03495-z"},{"key":"e_1_3_6_75_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01282-8"},{"key":"e_1_3_6_76_2","doi-asserted-by":"crossref","first-page":"xi12","DOI":"10.1093\/annonc\/mdz448","article-title":"35O\u2014Phase I clinical trial of PD-1 knockout anti-MUC1 CAR-T cells in the treatment of patients with non-small cell lung cancer","volume":"30","author":"Lin Y","year":"2019","unstructured":"Lin Y, Chen S, Zhong S, et al: 35O\u2014Phase I clinical trial of PD-1 knockout anti-MUC1 CAR-T cells in the treatment of patients with non-small cell lung cancer. Ann Oncol 30:xi12, 2019","journal-title":"Ann Oncol"},{"key":"e_1_3_6_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.07.020"},{"key":"e_1_3_6_78_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0460-x"},{"key":"e_1_3_6_79_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08261-8"},{"key":"e_1_3_6_80_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0297-y"},{"key":"e_1_3_6_81_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172898"},{"key":"e_1_3_6_82_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83416"},{"key":"e_1_3_6_83_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00753-0"},{"key":"e_1_3_6_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.05.011"},{"key":"e_1_3_6_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.505"},{"key":"e_1_3_6_86_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02182-7"},{"key":"e_1_3_6_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02462-0"},{"key":"e_1_3_6_88_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0051-2"},{"key":"e_1_3_6_89_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26073119"},{"key":"e_1_3_6_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2025.101612"},{"key":"e_1_3_6_91_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83092"},{"key":"e_1_3_6_92_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0168"},{"key":"e_1_3_6_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.04.023"},{"key":"e_1_3_6_94_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.2756"},{"key":"e_1_3_6_95_2","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/435745"},{"key":"e_1_3_6_96_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0038-z"},{"key":"e_1_3_6_97_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0153-5"},{"key":"e_1_3_6_98_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-9728-2_12"},{"key":"e_1_3_6_99_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-014-0026-0"},{"key":"e_1_3_6_100_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_3_6_101_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020578"},{"key":"e_1_3_6_102_2","first-page":"14","article-title":"Lymphodepletion\u2014An essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Review","author":"Lickefett B","year":"2023","unstructured":"Lickefett B, Chu L, Ortiz-Maldonado V, et al: Lymphodepletion\u2014An essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Review. Front Immunol 14, 2023","journal-title":"Front Immunol"},{"key":"e_1_3_6_103_2","doi-asserted-by":"crossref","first-page":"e008735","DOI":"10.1136\/jitc-2023-008735","article-title":"Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy","volume":"12","author":"Betof WA","year":"2024","unstructured":"Betof WA, Hamid O, Komanduri K, et al: Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy. J Immunother Cancer 12:e008735, 2024","journal-title":"J Immunother Cancer"},{"key":"e_1_3_6_104_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061501"},{"key":"e_1_3_6_105_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"e_1_3_6_106_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0564-6"},{"key":"e_1_3_6_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00077-2"},{"key":"e_1_3_6_108_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2024.04.075"},{"key":"e_1_3_6_109_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.03.006"},{"key":"e_1_3_6_110_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.24"},{"key":"e_1_3_6_111_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490565"},{"key":"e_1_3_6_112_2","article-title":"Infections in patients with solid tumors undergoing adoptive cellular therapy","author":"Avutu V","unstructured":"Avutu V, Algazaq JN, Seier K, et al: Infections in patients with solid tumors undergoing adoptive cellular therapy. Transplant Cell Ther 10.1016\/j.jtct.2025.02.017 [epub ahead of print on February 22, 2025]","journal-title":"Transplant Cell Ther"},{"key":"e_1_3_6_113_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa4967"},{"key":"e_1_3_6_114_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01618"},{"key":"e_1_3_6_115_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1417"},{"key":"e_1_3_6_116_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00315"},{"key":"e_1_3_6_117_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003092"},{"key":"e_1_3_6_118_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.05.026"},{"key":"e_1_3_6_119_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015634"},{"issue":"3","key":"e_1_3_6_120_2","first-page":"29","article-title":"Educating multidisciplinary care teams, patients, and caregivers on CAR T-cell therapy","volume":"10","author":"Beaupierre A","year":"2019","unstructured":"Beaupierre A, Kahle N, Lundberg R, et al: Educating multidisciplinary care teams, patients, and caregivers on CAR T-cell therapy. J Adv Pract Oncol 10:29-40, 2019 (suppl 3)","journal-title":"J Adv Pract Oncol"},{"key":"e_1_3_6_121_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002509"},{"key":"e_1_3_6_122_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14100"},{"key":"e_1_3_6_123_2","volume-title":"FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor CAR T Cell Immunotherapies","author":"US Food and Drug Administration","year":"2025","unstructured":"US Food and Drug Administration: FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor CAR T Cell Immunotherapies. FDA News Release, 2025. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-26-00119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T19:59:26Z","timestamp":1779307166000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-26-00119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":122,"alternative-id":["10.1200\/OP-26-00119"],"URL":"https:\/\/doi.org\/10.1200\/op-26-00119","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"2026-01-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"OP-26-00119"}}